UK committee grills GSK and Roche on data disclosure policies
This article was originally published in SRA
Executive Summary
More indications that the focus of the debate over wider clinical trial data disclosure has – at least in Europe – shifted away from commercial confidentiality to the protection of personal data came from testimony by pharmaceutical industry executives at this week's UK evidence session at the House of Commons' science and technology committee1.